AMGN,UPDATE 3-Amgen seeks to bolster drug pipeline with $10.4 bln Onyx buyUS STOCKS-Futures edge lower ahead of dataUS STOCKS-Wall Street ticks up as data eases Fed concernAmerican Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video        American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       NEW YORK, Aug 26 U.S. stocks edged higher in light volume on Monday after a steep drop in orders for long-lasting manufactured goods pushed back expectations the Federal Reserve will soon begin to wind down its economic stimulus.American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video         US STOCKS-Wall Street ticks up as data eases Fed concernAmerican Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video        American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       NEW YORK, Aug 26 U.S. stocks edged higher in light volume on Monday after a steep drop in orders for long-lasting manufactured goods pushed back expectations the Federal Reserve will soon begin to wind down its economic stimulus.American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video        * Amgen to buy Onyx Pharma for about $10.4 billion, Onyx shares riseUS STOCKS-Wall Street ticks up as data eases Fed concernAmerican Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video        American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       NEW YORK, Aug 26 U.S. stocks edged higher in light volume on Monday after a steep drop in orders for long-lasting manufactured goods pushed back expectations the Federal Reserve will soon begin to wind down its economic stimulus.American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video          US STOCKS-Futures edge lower ahead of dataUS STOCKS-Wall Street ticks up as data eases Fed concernAmerican Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video        American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       NEW YORK, Aug 26 U.S. stocks edged higher in light volume on Monday after a steep drop in orders for long-lasting manufactured goods pushed back expectations the Federal Reserve will soon begin to wind down its economic stimulus.American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video         US STOCKS-Wall Street ticks up as data eases Fed concernAmerican Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video        American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       NEW YORK, Aug 26 U.S. stocks edged higher in light volume on Monday after a steep drop in orders for long-lasting manufactured goods pushed back expectations the Federal Reserve will soon begin to wind down its economic stimulus.American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video        * Amgen to buy Onyx Pharma for about $10.4 billion, Onyx shares riseUS STOCKS-Wall Street ticks up as data eases Fed concernAmerican Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video        American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       NEW YORK, Aug 26 U.S. stocks edged higher in light volume on Monday after a steep drop in orders for long-lasting manufactured goods pushed back expectations the Federal Reserve will soon begin to wind down its economic stimulus.American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video         Aug 25 Amgen Inc struck a deal to buy cancer drug maker Onyx Pharmaceuticals Inc for about $10.4 billion on Sunday, as it moves to restock its product pipeline in response to declining sales of its flagship anemia drugs.US STOCKS-Futures edge lower ahead of dataUS STOCKS-Wall Street ticks up as data eases Fed concernAmerican Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video        American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       NEW YORK, Aug 26 U.S. stocks edged higher in light volume on Monday after a steep drop in orders for long-lasting manufactured goods pushed back expectations the Federal Reserve will soon begin to wind down its economic stimulus.American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video         US STOCKS-Wall Street ticks up as data eases Fed concernAmerican Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video        American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       NEW YORK, Aug 26 U.S. stocks edged higher in light volume on Monday after a steep drop in orders for long-lasting manufactured goods pushed back expectations the Federal Reserve will soon begin to wind down its economic stimulus.American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video        * Amgen to buy Onyx Pharma for about $10.4 billion, Onyx shares riseUS STOCKS-Wall Street ticks up as data eases Fed concernAmerican Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video        American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       NEW YORK, Aug 26 U.S. stocks edged higher in light volume on Monday after a steep drop in orders for long-lasting manufactured goods pushed back expectations the Federal Reserve will soon begin to wind down its economic stimulus.American Horner takes Vuelta lead after stage winUS STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video       US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      MIRADOR DE LOBEIRA, Spain American Chris Horner seized a solo victory on stage three of the Vuelta a Espana on Monday to claim the overall lead.US STOCKS-Wall St advances as durables data reduces Fed worryUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video      US STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     * Economic signs may cause Fed to delay scaling back stimulusUS STOCKS-Wall St dips after Kerry blasts Syria over chemical weaponsNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video     NEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    * Nations must stand up over Syria chemical weapons-Secretary of StateNEWSMAKER-Bradway's patient dealmaking brings Onyx to AmgenBradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video    Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   New YORK, Aug 26 Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Bradway's patient dealmaking brings Onyx to AmgenOnyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video   Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video  New YORK Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion.Onyx deal expected to give Amgen a big boost Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. | Video          
APC,RPT-UPDATE 2-India's ONGC to buy $2.64-bln stake in Anadarko Mozambique gas blockUPDATE 3-India's ONGC to buy $2.64-bln stake in Anadarko Mozambique gas blockIndia's ONGC to buy $2.64-billion stake in Anadarko Mozambique gas block MUMBAI/NEW YORK India's Oil and Natural Gas Corp  has agreed to buy 10 percent in a gas field offshore Mozambique from Anadarko Petroleum Corp for $2.64 billion, as the explorer looks to offset diminishing supplies from domestic gas fields by buying overseas assets.  India's ONGC to buy $2.64-billion stake in Anadarko Mozambique gas block MUMBAI/NEW YORK India's Oil and Natural Gas Corp  has agreed to buy 10 percent in a gas field offshore Mozambique from Anadarko Petroleum Corp for $2.64 billion, as the explorer looks to offset diminishing supplies from domestic gas fields by buying overseas assets. * ONGC expects cash transaction to close by next March -company officialIndia's ONGC to buy $2.64-billion stake in Anadarko Mozambique gas block MUMBAI/NEW YORK India's Oil and Natural Gas Corp  has agreed to buy 10 percent in a gas field offshore Mozambique from Anadarko Petroleum Corp for $2.64 billion, as the explorer looks to offset diminishing supplies from domestic gas fields by buying overseas assets.   UPDATE 3-India's ONGC to buy $2.64-bln stake in Anadarko Mozambique gas blockIndia's ONGC to buy $2.64-billion stake in Anadarko Mozambique gas block MUMBAI/NEW YORK India's Oil and Natural Gas Corp  has agreed to buy 10 percent in a gas field offshore Mozambique from Anadarko Petroleum Corp for $2.64 billion, as the explorer looks to offset diminishing supplies from domestic gas fields by buying overseas assets.  India's ONGC to buy $2.64-billion stake in Anadarko Mozambique gas block MUMBAI/NEW YORK India's Oil and Natural Gas Corp  has agreed to buy 10 percent in a gas field offshore Mozambique from Anadarko Petroleum Corp for $2.64 billion, as the explorer looks to offset diminishing supplies from domestic gas fields by buying overseas assets. * ONGC expects cash transaction to close by next March -company officialIndia's ONGC to buy $2.64-billion stake in Anadarko Mozambique gas block MUMBAI/NEW YORK India's Oil and Natural Gas Corp  has agreed to buy 10 percent in a gas field offshore Mozambique from Anadarko Petroleum Corp for $2.64 billion, as the explorer looks to offset diminishing supplies from domestic gas fields by buying overseas assets.  * ONGC expects cash transaction to close by next March -company officialUPDATE 3-India's ONGC to buy $2.64-bln stake in Anadarko Mozambique gas blockIndia's ONGC to buy $2.64-billion stake in Anadarko Mozambique gas block MUMBAI/NEW YORK India's Oil and Natural Gas Corp  has agreed to buy 10 percent in a gas field offshore Mozambique from Anadarko Petroleum Corp for $2.64 billion, as the explorer looks to offset diminishing supplies from domestic gas fields by buying overseas assets.  India's ONGC to buy $2.64-billion stake in Anadarko Mozambique gas block MUMBAI/NEW YORK India's Oil and Natural Gas Corp  has agreed to buy 10 percent in a gas field offshore Mozambique from Anadarko Petroleum Corp for $2.64 billion, as the explorer looks to offset diminishing supplies from domestic gas fields by buying overseas assets. * ONGC expects cash transaction to close by next March -company officialIndia's ONGC to buy $2.64-billion stake in Anadarko Mozambique gas block MUMBAI/NEW YORK India's Oil and Natural Gas Corp  has agreed to buy 10 percent in a gas field offshore Mozambique from Anadarko Petroleum Corp for $2.64 billion, as the explorer looks to offset diminishing supplies from domestic gas fields by buying overseas assets.   
BAC,CORRECTED-Brazil's Anima hires Itaú, Bank of America for IPO -sources (Corrects paragraph 5 to change name of company mulling IPO to Ser Educacional instead of Ser Educação, removes reference to Abril Educação as Ser is not a unit of Abril; adds new story number for IFR report) 
BBY,Schulze plans to start selling Best Buy shares later this year Aug 26 Richard Schulze, the founder and largest shareholder of Best Buy Co Inc, has informed the world's largest consumer electronics chain about his plan to start selling its stock starting this fall, according to a regulatory filing on Monday. 
C,UPDATE 2-Ackman turns back on J.C. Penney, sells entire stake in retailer (Adds details on company and Ackman's fund, analyst comment) 
EA,In digital age games makers still feel need to meet and greet * Wards off growing trend of companies holding own events 
FB,U.S. judge approves Facebook privacy settlement over adsREFILE-Nasdaq trading halt exposes communication gaps when crisis hits * Communication protocol for market mishaps needed-traders  REFILE-Nasdaq trading halt exposes communication gaps when crisis hits * Communication protocol for market mishaps needed-traders SAN FRANCISCO, Aug 26 A U.S. judge on Monday granted final approval to Facebook's $20 million settlement of a lawsuit over targeted advertising despite objections that the deal did not go far enough to protect children's privacy.REFILE-Nasdaq trading halt exposes communication gaps when crisis hits * Communication protocol for market mishaps needed-traders  
GS,Goldman puts 4 on leave after fallout from trading glitch-reportGoldman puts four on leave after fallout from trading glitch: reportSTXNEWS LATAM-Goldman Sachs cuts stake in Brazil's GafisaGoldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.   Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  Goldman Sachs Group Inc has sold 12.47 million common shares of Brazilian homebuilder Gafisa SA, reducing its ownership stake in the company to 3.2 percent, according to a securities filing on Monday.Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.    STXNEWS LATAM-Goldman Sachs cuts stake in Brazil's GafisaGoldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.   Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  Goldman Sachs Group Inc has sold 12.47 million common shares of Brazilian homebuilder Gafisa SA, reducing its ownership stake in the company to 3.2 percent, according to a securities filing on Monday.Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.   Goldman Sachs Group Inc  put four senior technology specialists on administrative leave after a trading glitch that led to a flood of erroneous options trades, the Financial Times reported, citing people familiar with the situation.STXNEWS LATAM-Goldman Sachs cuts stake in Brazil's GafisaGoldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.   Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  Goldman Sachs Group Inc has sold 12.47 million common shares of Brazilian homebuilder Gafisa SA, reducing its ownership stake in the company to 3.2 percent, according to a securities filing on Monday.Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.     Goldman puts four on leave after fallout from trading glitch: reportSTXNEWS LATAM-Goldman Sachs cuts stake in Brazil's GafisaGoldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.   Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  Goldman Sachs Group Inc has sold 12.47 million common shares of Brazilian homebuilder Gafisa SA, reducing its ownership stake in the company to 3.2 percent, according to a securities filing on Monday.Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.    STXNEWS LATAM-Goldman Sachs cuts stake in Brazil's GafisaGoldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.   Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  Goldman Sachs Group Inc has sold 12.47 million common shares of Brazilian homebuilder Gafisa SA, reducing its ownership stake in the company to 3.2 percent, according to a securities filing on Monday.Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.   Goldman Sachs Group Inc  put four senior technology specialists on administrative leave after a trading glitch that led to a flood of erroneous options trades, the Financial Times reported, citing people familiar with the situation.STXNEWS LATAM-Goldman Sachs cuts stake in Brazil's GafisaGoldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.   Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  Goldman Sachs Group Inc has sold 12.47 million common shares of Brazilian homebuilder Gafisa SA, reducing its ownership stake in the company to 3.2 percent, according to a securities filing on Monday.Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.    Aug 26 Goldman Sachs Group Inc put four senior technology specialists on administrative leave after a trading glitch that led to a flood of erroneous options trades, the Financial Times reported, citing people familiar with the situation.Goldman puts four on leave after fallout from trading glitch: reportSTXNEWS LATAM-Goldman Sachs cuts stake in Brazil's GafisaGoldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.   Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  Goldman Sachs Group Inc has sold 12.47 million common shares of Brazilian homebuilder Gafisa SA, reducing its ownership stake in the company to 3.2 percent, according to a securities filing on Monday.Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.    STXNEWS LATAM-Goldman Sachs cuts stake in Brazil's GafisaGoldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.   Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  Goldman Sachs Group Inc has sold 12.47 million common shares of Brazilian homebuilder Gafisa SA, reducing its ownership stake in the company to 3.2 percent, according to a securities filing on Monday.Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.   Goldman Sachs Group Inc  put four senior technology specialists on administrative leave after a trading glitch that led to a flood of erroneous options trades, the Financial Times reported, citing people familiar with the situation.STXNEWS LATAM-Goldman Sachs cuts stake in Brazil's GafisaGoldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.   Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  Goldman Sachs Group Inc has sold 12.47 million common shares of Brazilian homebuilder Gafisa SA, reducing its ownership stake in the company to 3.2 percent, according to a securities filing on Monday.Goldman losses from options glitch in tens of millions -sourceUPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.  UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood. Aug 26 Goldman Sachs Group Inc lost tens of millions of dollars after a computer glitch led to a flood of erroneous options trades last week, a source close to the matter said on Monday.UPDATE 3-BATS, Direct Edge merge as stock trading decline catches up Aug 26 After three years of on-again, off-again deal talks, BATS Global Markets Inc Chief Executive Joe Ratterman and Direct Edge Holdings LLC's Bill O'Brien met in April over lunch at a restaurant in New York's Tribeca neighborhood.     
MSFT,Analysis: New Microsoft CEO faces big choices post-BallmerRPT-Microsoft, Motorola set for second round of trial over patents SEATTLE, Aug 25 Microsoft Corp takes on Google's Motorola Mobility unit this week in the second of two landmark trials between the companies that delve into hot disputes over the patents behind smartphone and Internet technology.  RPT-Microsoft, Motorola set for second round of trial over patents SEATTLE, Aug 25 Microsoft Corp takes on Google's Motorola Mobility unit this week in the second of two landmark trials between the companies that delve into hot disputes over the patents behind smartphone and Internet technology. SEATTLE The next CEO of Microsoft Corp has one big decision to make: press on with retiring chief executive Steve Ballmer's ambitious plan to transform the software giant into a broad-based devices and services company, or jettison that idea and rally resources around its proven strength in business software.RPT-Microsoft, Motorola set for second round of trial over patents SEATTLE, Aug 25 Microsoft Corp takes on Google's Motorola Mobility unit this week in the second of two landmark trials between the companies that delve into hot disputes over the patents behind smartphone and Internet technology.  
NDAQ,REFILE-Nasdaq trading halt exposes communication gaps when crisis hits * Communication protocol for market mishaps needed-traders 
TGT,New apps help shoppers identify items using image recognition TORONTO, Aug 26 A new app lets shoppers flipping through retail flyers purchase items that catch their eye using image recognition technology. 
UTX,United Tech, US reach $1 bln-plus deal for F-35 engines -sourcesUS STOCKS-Wall St advances as durables data reduces Fed worry * Economic signs may cause Fed to delay scaling back stimulus  US STOCKS-Wall St advances as durables data reduces Fed worry * Economic signs may cause Fed to delay scaling back stimulus WASHINGTON, Aug 26 Pratt & Whitney, a unit of United Technologies Corp has reached agreement in principle with the Pentagon on a contract to build 39 engines for a sixth batch of F-35 Joint Strike Fighters, three sources familiar with the deal said Monday.US STOCKS-Wall St advances as durables data reduces Fed worry * Economic signs may cause Fed to delay scaling back stimulus  
